NCT04896541View on ClinicalTrials.gov

Phase I Double-blind, Placebo-controlled Study of AZD7442

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

June 14, 2022

Study Completion Date

June 14, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

AZD7442 300 mg IM(male)

Single dose of 300 mg of AZD7442 or saline placebo on Day 1.

BIOLOGICAL

AZD7442 600 mg IM (male)

Single dose of 600 mg of AZD7442 or saline placebo on Day 1.

BIOLOGICAL

AZD7442 300 mg IV (male and female)

Single dose of 300 mg of AZD7442 or saline placebo on Day 1.

BIOLOGICAL

AZD7442 1000 mg IV (male)

Single dose 1000 mg of AZD7442 or saline placebo on Day 1.

Trial Locations (1)

812-0025

Research Site, Fukuoka

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY